# Leora Horn

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/leora-horn/

## Facts

| Field | Value |
| --- | --- |
| Citations | 17,832 |
| Field | Lung Cancer Treatments and Mutations |
| h-index | 49 |
| i10-index | 101 |
| Last Known Institution | Vanderbilt University |
| OpenAlex ID | https://openalex.org/A5062894702 |
| ORCID iD | https://orcid.org/0000-0003-2070-2547 |
| Works | 275 |

## Researcher papers

- [First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer](https://scholariq.org/papers/first-line-atezolizumab-plus-chemotherapy-in-extensive-stage-small-cell-lung/)
- [AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer](https://scholariq.org/papers/azd9291-in-egfr-inhibitor-resistant-non-small-cell-lung-cancer/)
- [Tepotinib in Non–Small-Cell Lung Cancer with <i>MET</i> Exon 14 Skipping Mutations](https://scholariq.org/papers/tepotinib-in-non-small-cell-lung-cancer-with-i-met-i-exon-14-skipping-mutations/)
- [Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133)](https://scholariq.org/papers/updated-overall-survival-and-pd-l1-subgroup-analysis-of-patients-with-extensive/)
- [COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study](https://scholariq.org/papers/covid-19-in-patients-with-thoracic-malignancies-teravolt-first-results-of-an/)
- [Phase III Randomized Trial of Ipilimumab Plus Etoposide and Platinum Versus Placebo Plus Etoposide and Platinum in Extensive-Stage Small-Cell Lung Cancer](https://scholariq.org/papers/phase-iii-randomized-trial-of-ipilimumab-plus-etoposide-and-platinum-versus/)
- [Non–Small Cell Lung Cancer, Version 6.2015](https://scholariq.org/papers/non-small-cell-lung-cancer-version-6-2015/)
- [TATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer](https://scholariq.org/papers/tatton-a-multi-arm-phase-ib-trial-of-osimertinib-combined-with-selumetinib/)
- [Burnout and Career Satisfaction Among US Oncologists](https://scholariq.org/papers/burnout-and-career-satisfaction-among-us-oncologists/)
- [Nivolumab Monotherapy and Nivolumab Plus Ipilimumab in Recurrent Small Cell Lung Cancer: Results From the CheckMate 032 Randomized Cohort](https://scholariq.org/papers/nivolumab-monotherapy-and-nivolumab-plus-ipilimumab-in-recurrent-small-cell-lung/)
- [Ensartinib vs Crizotinib for Patients With Anaplastic Lymphoma Kinase−Positive Non–Small Cell Lung Cancer](https://scholariq.org/papers/ensartinib-vs-crizotinib-for-patients-with-anaplastic-lymphoma-kinase-positive/)
- [Osimertinib Plus Durvalumab versus Osimertinib Monotherapy in EGFR T790M–Positive NSCLC following Previous EGFR TKI Therapy: CAURAL Brief Report](https://scholariq.org/papers/osimertinib-plus-durvalumab-versus-osimertinib-monotherapy-in-egfr-t790m/)

## Researcher topics

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)
- [Cancer therapeutics and mechanisms](https://scholariq.org/topics/cancer-therapeutics-and-mechanisms/)
- [Lung Cancer Diagnosis and Treatment](https://scholariq.org/topics/lung-cancer-diagnosis-and-treatment/)
- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)

## Researcher university

- [Vanderbilt University](https://scholariq.org/institutions/vanderbilt-university/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.